Income Taxes (Tables)

12 Months Ended

Jan. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

The components of total loss from continuing operations before income taxes are as follows (in thousands):

	Fiscal Year Ended January 31,
	2025		2024 (1)		2023 (1)
US	$	(108,336)	$	14,328	$	(4,877)
Foreign	22,543		(174,895)		(170,417)
Loss before income taxes	$	(85,793)	$	(160,567)	$	(175,294)

(1) The Company revised the prior-period balances. Refer to “Note 2. Basis of Presentation and Summary of Significant Accounting Policies”.

Schedule of Components of Income Tax Expense (Benefit)

The provision for (benefit from) income taxes consisted of the following (in thousands):

	Fiscal Year Ended January 31,
	2025		2024		2023
Current:
Federal and State	$	2,028	$	(1,768)	$	1,432
Foreign	(68,021)		257,384		1,954
Total current	$	(65,993)	$	255,616	$	3,386
Deferred:
Federal and State	$	(3)	$	(810)	$	614
Foreign	(10,678)		10,339		30
Total deferred	$	(10,681)	$	9,529	$	644
Provision for (benefit from) income taxes	$	(76,674)	$	265,145	$	4,030

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate is as follows:

	Fiscal Year Ended January 31,
	2025		2024 (1)		2023 (1)
Tax at federal statutory rate	21.0	%	21.0	%	21.0	%
State, net of federal benefit	(0.1)		(0.1)		(0.2)
Stock-based compensation	6.9		2.4		(0.4)
Non-deductible Executive Compensation	(12.0)		(4.7)		(1.6)
Research tax credit	5.5		6.2		2.7
Foreign rate differential	(2.8)		(1.8)		5.5
Change in valuation allowance	(4.5)		(83.3)		(29.0)
Foreign derived intangible income deduction	0.2		—		0.6
Unrecognized tax benefits	77.5		(105.3)		(1.1)
Other	(2.3)		0.5		0.2
Total	89.4	%	(165.1)	%	(2.3)	%

(1) The Company revised the prior-period balances. Refer to “Note 2. Basis of Presentation and Summary of Significant Accounting Policies”.

Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company's deferred tax assets and liabilities are as follows (in thousands):

	January 31,
	2025		2024
Deferred tax assets:
Net operating loss carryforwards	$	92,432	$	85,348
Research tax credits	14,942		14,031
Deferred revenue	12,419		6,812
Accruals and other assets	2,024		6,237
Capitalized R&D	107,035		70,921
Intangibles	98,690		110,160
Interest expense limitation	10,379		35,085
Unrealized FX	282		—
Stock-based compensation	8,829		6,679
Gross deferred tax assets	347,032		335,273
Valuation allowance	(323,710)		(328,385)
Net deferred tax assets	23,322		6,888
Deferred tax liabilities:
Deferred contract acquisition costs	(13,628)		(7,019)
Fixed assets	(92)		(191)
Unrealized foreign exchange adjustments	—		(10,024)
Federal effects of disregarded entities	(9,277)		—
Other	—		(23)
Net deferred tax assets (liabilities)	$	325	$	(10,369)

Schedule of Unrecognized Tax Benefits Roll Forward

The reconciliation of the Company's unrecognized tax benefits is as follows (in thousands):

	January 31,
	2025		2024
Beginning balance	$	402,728	$	13,364
Gross increases due to tax positions taken in prior periods	9,785		324,364
Gross increases due to tax position taken in current period	3,510		65,001
Gross decreases due to settlement tax payment	(137,262)		—
Gross decreases due to settlements with taxing authorities	(253,191)		—
Gross decreases due to lapses in applicable statutes of limitations	—		(1)
Ending balance	$	25,570	$	402,728